Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176127
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Doménech, Mónica | - |
dc.contributor.author | Casas Rodríguez, Rosa M. | - |
dc.contributor.author | Ruíz León, Ana María | - |
dc.contributor.author | Sobrino, Javier | - |
dc.contributor.author | Ros Rahola, Emilio | - |
dc.contributor.author | Estruch Riba, Ramon | - |
dc.date.accessioned | 2021-04-12T13:21:46Z | - |
dc.date.available | 2021-04-12T13:21:46Z | - |
dc.date.issued | 2019-04-26 | - |
dc.identifier.issn | 2072-6643 | - |
dc.identifier.uri | http://hdl.handle.net/2445/176127 | - |
dc.description.abstract | Background: Cholesterol-lowering nutraceuticals are useful in the management of moderate hypercholesterolemia. Methods: In a parallel-group, randomized, placebo-controlled double-blind trial we evaluated the effects on plasma total cholesterol, low-density lipoprotein cholesterol (LDL-c), and inflammatory biomarkers of a nutraceutical combination (Aquilea Colesterol®) containing phytosterols (1.5 g), red yeast rice providing monacolin K (10 mg), hydroxytyrosol (5 mg), and plasma cholesterol values >5.17 mmol/L (>200 mg/dL) and LDL-c >2.97 mmol/L (>115 mg/dL). At baseline and at one and three months we recorded dietary habits; anthropometric parameters; blood pressure; lipid profile; fasting glucose; liver, renal, and muscle function tests, C-reactive protein (hs-CRP); and interleukin-6. Results: 13 men and 27 women (mean age 61.8 years) completed the trial; 20 participants received the nutraceutical and 20 received placebo. No adverse effects were noted. Compared to placebo, at one and three months the nutraceutical reduced total cholesterol by 11.4% and 14.1%, LDL-c by 19.8% and 19.7%, and apolipoprotein B by 12.4% and 13.5%, respectively (p < 0.001; all). hs-CRP decreased significantly (p = 0.021) in the nutraceutical group. Conclusion: The nutraceutical Aquilea Colesterol® is useful for reducing total cholesterol, LDL-c, and inflammation in individuals with moderate hypercholesterolemia. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/nu11050949 | - |
dc.relation.ispartof | Nutrients, 2019, vol. 11, num. 5, p. 949 | - |
dc.relation.uri | https://doi.org/10.3390/nu11050949 | - |
dc.rights | cc-by (c) Doménech, Mónica et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Aliments funcionals | - |
dc.subject.classification | Proteïnes | - |
dc.subject.classification | Colesterol | - |
dc.subject.other | Functional foods | - |
dc.subject.other | Proteins | - |
dc.subject.other | Cholesterol | - |
dc.title | Effects of a Novel Nutraceutical Combination (Aquilea Colesterol®) on the Lipid Profile and Inflammatory Biomarkers: A Randomized Control Trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 705305 | - |
dc.date.updated | 2021-04-12T13:21:47Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31035469 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
705305.pdf | 842.92 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License